3004 Background: DEP CTX is a highly optimized dendrimer nanoparticle formulation of
cabazitaxel that achieves sustained cytotoxic drug delivery to tumors via enhanced …

Background Dendrimers enable sustained delivery of cytotoxic drugs and achieve selective
tumour targeting via an enhanced permeability and retention effect. DEP cabazitaxel is a …

Background• Cabazitaxel is widely used in the treatment of prostate cancer• Conventional
formulations of cabazitaxel contain polysorbate 80 requiring routine pre-medication with …

Background• Advanced esophago-gastric cancers (EGC):-significant unmet medical need,
very poor prognosis, limited available treatments-progress rapidly with 1-year survival rate of …

Docetaxel (Taxotere®) and cabazitaxel (Jevtana®) are mitotic inhibitors that function as
effective cytotoxic agents and are widely used in many chemotherapy regimens. However …

The antitumor efficacy of various paclitaxel (PTX) and docetaxel (DTX) formulations in
clinical applications is seriously affected by drug resistance. Cabazitaxel, a second …

Taxane-based chemotherapeutics are clinically available as frontline treatment regimens for
cervical cancer. However, drug resistance and life-threatening toxicity impair the clinical …

Background: Cabazitaxel (CBZ) is a second-generation taxane that has the potential to
overcome taxane-resistance due to the low affinity for the P-glycoprotein efflux pump …

Effective treatment of metastatic castration resistant prostate cancer (mCRPC) remains an
unmet challenge. Cabazitaxel (CBZ) is approved for mCRPC after docetaxel (DTX) failure …

233 Background: BIND-014 is a novel PSMA-targeted Accurin (polymeric nanoparticle) that
contains docetaxel (D). BIND-014 is anticipated to improve the therapeutic index of D by …